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patients with mild-to-moderate asthma [1]. In addition, SA can come up concomitantly with
other chronic diseases, such as rhinosinusitis and chronic obstructive pulmonary disease
(COPD) [2]. Despite the high asthma prevalence worldwide, its pathophysiology, phenotypes,
endotypes, biomarkers, and treatment still need to be elucidated, therefore, being of great
interest of study for the scientific community [13].
3. Pathophysiology of severe asthma
The main pathophysiological feature of asthma is the bronchial inflammation resulting from
interactions between airway structural cells and the innate/adaptive immune system. Struc-
tural cells of the lung, among them, epithelial cells, endothelial cells, and fibroblasts, release
inflammatory mediators, mainly chemokines, and actively participate in the inflammatory
process by attracting blood cells to the inflamed site. Thus, the development of the inflamma-
tory response initially orchestrated by the lung structural cells in asthma also depends on
innate immunity cells such as eosinophils, neutrophils, macrophages, mast cells, NKT cells,
γδ-Tcells, inactive lymphoid cells (ILCs) and dendritic cells, and also on adaptive immunity
cells represented by T and B cells. Interactions among these cells and the release of various
inflammatory proteins, including cytokines, chemokines, adhesion molecules, eicosanoids,
histamine, and nitric oxide (NO), promote the bronchial inflammatory process [14–16]. This
inflammatory process is a common feature to all atopic asthmatic patients including those with
the severe phenotype.
Histological addresses indicate that bronchial biopsies of asthmatic individuals reveal tissue
structural changes, such as collagen deposition under the epithelium, which is described as the
thickening of the basement membrane and of the smooth muscle layer of the airways due to
the hyperplasia and the hypertrophy of the smooth muscle, which is most commonly observed
in patients with severe asthma [17].
Further, there is an increase if the number of blood vessels (angiogenesis) in response to increased
secretion of the vessel-endothelial growth factor (VEGF) [18] as well as an increase in mucus
secretion commonly observed in biopsies of asthmatic patients, due to an increase in the number
of secreting-mucus goblet cell in the epithelium and in the size of submucosal glands [19].
Once asthma presents a complex inflammatory process regulated by immune cells and structural
bronchial cells collaborating for the initiation, exacerbation, and maintenance of the inflamma-
tory process, all of these events might lead to irreversible bronchial structural changes and the
airway remodeling which strongly contribute to severe development of asthma [15].
3.1. Airway remodeling
Airway remodeling can be defined as a set of changes in the composition, content and organi-
zation of the cellular and molecular constituents of the airway wall. The airway remodeling
includes epithelial damage, cilial dysfunction, increased thickness of sub-epithelial basement
membrane, angiogenesis, and neuronal proliferation. Also, it increases airway smooth muscle
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